热门出版物 - 学术资源搜索

h5 指数:97
h5 中位数:143

h5 指数是指在过去整整 5 年中所发表文章的 h 指数。h 指在 2018-2022 年间发表的 h 篇文章每篇至少都被引用过 h 次的最大值。隐藏

出版物的 h5 中位数，是指出版物的 h5 指数所涵盖的所有文章获得的引用次数的中位值。隐藏

#4 Pulmonology
#18 Oncology

标题/作者	引用次数	年份
Pulmonary Pathology of Early-Phase 2019 Novel Coronavirus (COVID-19) Pneumonia in Two Patients With Lung Cancer S Tian, W Hu, L Niu, H Liu, H Xu, SY Xiao Journal of Thoracic Oncology 15 (5), 700-704	1376	2020
PD-L1 Immunohistochemistry Assays for Lung Cancer: Results from Phase 1 of the Blueprint PD-L1 IHC Assay Comparison Project FR Hirsch, A McElhinny, D Stanforth, J Ranger-Moore, M Jansson, ... Journal of Thoracic Oncology 12 (2), 208-222	1054	2017
Updated Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment With Targeted Tyrosine Kinase Inhibitors: Guideline From the College of American Pathologists, the International Association for the Study of Lung Cancer, and the Association for Molecular Pathology NI Lindeman, PT Cagle, DL Aisner, ME Arcila, MB Beasley, EH Bernicker, ... Journal of Thoracic Oncology 13 (3), 323-358	1038	2018
Checkpoint Inhibitors in Metastatic EGFR-Mutated Non–Small Cell Lung Cancer—A Meta-Analysis CK Lee, J Man, S Lord, M Links, V Gebski, T Mok, JCH Yang Journal of Thoracic Oncology 12 (2), 403-407	581	2017
Potential Predictive Value of TP53 and KRAS Mutation Status for Response to PD-1 Blockade Immunotherapy in Lung Adenocarcinoma ZY Dong, WZ Zhong, SY Liu, Z Xie, SP Wu, YL Wu JOURNAL OF THORACIC ONCOLOGY 12 (1), S432-S433	545	2017
PD-L1 Immunohistochemistry Comparability Study in Real-Life Clinical Samples: Results of Blueprint Phase 2 Project MS Tsao, KM Kerr, M Kockx, MB Beasley, AC Borczuk, J Botling, ... Journal of Thoracic Oncology 13 (9), 1302-1311	490	2018
Liquid Biopsy for Advanced Non-Small Cell Lung Cancer (NSCLC): A Statement Paper from the IASLC C Rolfo, PC Mack, GV Scagliotti, P Baas, F Barlesi, TG Bivona, RS Herbst, ... Journal of Thoracic Oncology 13 (9), 1248-1268	415	2018
A Phase II Study of Pembrolizumab in EGFR-Mutant, PD-L1+, Tyrosine Kinase Inhibitor Naïve Patients With Advanced NSCLC A Lisberg, A Cummings, JW Goldman, K Bornazyan, N Reese, T Wang, ... Journal of Thoracic Oncology 13 (8), 1138-1145	341	2018
Cancer of the Esophagus and Esophagogastric Junction: An Eighth Edition Staging Primer TW Rice, H Ishwaran, MK Ferguson, EH Blackstone, P Goldstraw Journal of Thoracic Oncology 12 (1), 36-42	304	2017
Three-Year Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC—Update from PACIFIC JE Gray, A Villegas, D Daniel, D Vicente, S Murakami, R Hui, T Kurata, ... Journal of Thoracic Oncology 15 (2), 288-293	284	2020
Early Immune-Related Adverse Events and Association with Outcome in Advanced Non–Small Cell Lung Cancer Patients Treated with Nivolumab: A Prospective Cohort Study S Teraoka, D Fujimoto, T Morimoto, H Kawachi, M Ito, Y Sato, K Nagata, ... Journal of Thoracic Oncology 12 (12), 1798-1805	283	2017
Updated Efficacy and Safety Data and Impact of the EML4-ALK Fusion Variant on the Efficacy of Alectinib in Untreated ALK-Positive Advanced Non–Small Cell Lung Cancer in the Global Phase III ALEX Study DR Camidge, R Dziadziuszko, S Peters, T Mok, J Noe, M Nowicka, ... Journal of Thoracic Oncology 14 (7), 1233-1243	260	2019
Targeting MET in Lung Cancer: Will Expectations Finally Be MET? A Drilon, F Cappuzzo, SHI Ou, DR Camidge Journal of Thoracic Oncology 12 (1), 15-26	254	2017
PL02. 05 Effects of Volume CT Lung Cancer Screening: Mortality Results of the NELSON Randomised-Controlled Population Based Trial H De Koning, C Van Der Aalst, K Ten Haaf, M Oudkerk Journal of Thoracic Oncology 13 (10), S185	245	2018
The IASLC Lung Cancer Staging Project: External Validation of the Revision of the TNM Stage Groupings in the Eighth Edition of the TNM Classification of Lung Cancer K Chansky, FC Detterbeck, AG Nicholson, VW Rusch, E Vallières, ... Journal of Thoracic Oncology 12 (7), 1109-1121	242	2017
Third-Line Nivolumab Monotherapy in Recurrent SCLC: CheckMate 032 N Ready, AF Farago, F de Braud, A Atmaca, MD Hellmann, JG Schneider, ... Journal of Thoracic Oncology 14 (2), 237-244	222	2019
Plasma ctDNA Analysis for Detection of the EGFR T790M Mutation in Patients with Advanced Non–Small Cell Lung Cancer S Jenkins, JCH Yang, SS Ramalingam, K Yu, S Patel, S Weston, R Hodge, ... Journal of Thoracic Oncology 12 (7), 1061-1070	220	2017
Pneumonitis in Non–Small Cell Lung Cancer Patients Receiving Immune Checkpoint Immunotherapy: Incidence and Risk Factors K Suresh, KR Voong, B Shankar, PM Forde, DS Ettinger, KA Marrone, ... Journal of Thoracic Oncology 13 (12), 1930-1939	209	2018
Atezolizumab in Combination With Carboplatin and Nab-Paclitaxel in Advanced Squamous NSCLC (IMpower131): Results From a Randomized Phase III Trial R Jotte, F Cappuzzo, I Vynnychenko, D Stroyakovskiy, ... Journal of Thoracic Oncology 15 (8), 1351-1360	205	2020
Nivolumab Versus Docetaxel in a Predominantly Chinese Patient Population With Previously Treated Advanced NSCLC: CheckMate 078 Randomized Phase III Clinical Trial YL Wu, S Lu, Y Cheng, C Zhou, J Wang, T Mok, L Zhang, HY Tu, L Wu, ... Journal of Thoracic Oncology 14 (5), 867-875	202	2019

1 - 20

计算机程序会自动估算并确定日期和引用次数。